Tuesday, 13th November Clinical Oncology Society of Australia Annual Scientific Meeting 2018

Improvement and implementation sciences are increasingly recognised as critical to ensuring quality of cancer care and timely adoption of best evidence into clinical practice. Research funding bodies require that research proposals consider how research findings will be translated into practice making knowledge of improvement and implementation necessary for both research and practice. This session will outline fundamental concepts of improvement science and implementation science and explore how they can be utilised in clinical practice to improve outcomes and increase value and how they can strengthen research applications to make them more competitive.

Chair: Bogda Koczwara 
Speakers: Bogda Koczwara, Christine Paul

This breakfast session is supported by COSA 

Family caregivers regularly attend consultations as patients’ supporters / advocates and often provide unpaid, personalised care to cancer patients. When informed and empowered, family caregivers can be valuable partners in cancer care. However, research shows that oncology clinicians do not always meaningfully engage with family caregivers. Also, some family members can introduce challenges, such as if they dominate the patient, request private patient information, disagree with the patient’s treatment wishes, or display anger towards staff. Building a positive working relationship with family caregivers and managing these challenges requires confidence and skill.

The TRIO Guidelines for communicating with family caregivers provide clear, specific, and evidence-based recommendations for oncology health professionals interacting with a patient’s family.

This session will provide an overview of the TRIO Guidelines, and will highlight specific behaviours and phrases clinicians can use to build a productive relationship with their patients’ family caregivers.

Professionally produced short films will be featured, which demonstrate skills from the TRIO Guidelines used in common clinical scenarios. Attendees will be provided with a hardcopy booklet of the TRIO Guidelines.

Oncology health professionals, researchers, and consumers are invited to attend the TRIO Guidelines breakfast launch.

Chair: Christobel Saunders 
Speakers: Ilona Juraskova, Phyllis Butow, Rebekah Laidsaar-Powell 

This breakfast session is supported by COSA 

Welcome by COSA President

Welcome to Country by local indigenous group

• Refining systemic therapy in GOJ tumours - can we cure more patients? - Dirk Arnold
• Surgical perspective TBC - Mohammed Ballal
• Pre- or Post-operative chemoradiation for GE junction cancer - Theodore Hong
• Action against cancer-related malnutrition – an international perspective in the age of obesity - Marian A.E. de van der Schueren

Dirk Arnold sponsored by Merck

• Genetics in mesothelioma - Dean Fennell
• Management of Familial Adenomatous Polyposis (FAP) - Marina H Wallace
• Inherited cancer syndromes: tailoring surveillance to the individual - Hooi C Ee
• Epidemiology of lynch syndrome - Mark Jenkins
• Facilitating family understanding, adjustment and communication when "it's in the genes" - Kim Hobbs

• Cannabis and the Endocannabinoid System. - Justin S Sinclair
• Medicinal cannabis – regulation, access and efficacy - John Skerritt
• Using knowledge of clinical pharmacology and therapeutics to guide choice of product and dose in clinical trials - Jennifer Martin
• Cancer Pain and Cannabis - Stephen Clarke
•   How are Oncology Clinic Conversations changing with the advent of legalising Medical Marijuana    - Rob Zielinski

• Protons in radiation oncology - Theodore Hong
• Upper gastro-intestinal cancers challenges and potential benefits in charged particle therapies - Mark Lee
• A Primer on Proton Therapy for the non-Radiation Oncologist - Peter Gorayski

Panel discussion at the end

• Focusing and sustaining cancer surgical care for high-risk procedures – oesophagectomies and pancreatectomies in NSW - Arthur Richardson
• Is survival improving for patients diagnosed with small intestinal neuroendocrine tumours in Queensland? - David Wyld
• A pilot study of patients' preferences for upfront resection versus a ‘watch and wait’ approach after neoadjuvant long course chemoradiation for locally advanced rectal cancer: what is avoiding surgery worth? - Ashray Gunjur
• Australian consensus statement on hepatitis B management during immunosuppression for haematological and solid-organ malignancies - Sue-Anne McLachlan
• Liver cancer knowledge in Arabic and Assyrian communities in Sydney: results of a community consultation - Monica C Robotin
• Utilisation of adjuvant chemotherapy for people with stage III colon cancer in NSW    - Hui You

• Development of Cancer-specific Manualised Depression Treatment - Laura Kirsten
• Technology supported self-guided nutrition and physical activity interventions in adults with cancer: a systematic review - Nicole Kiss
• Personalised supportive care for patients receiving 5-fluorouracil (5-FU): Analysis of multivariate SNP risk prediction for GI toxicity - Samantha K Korver
• Unmet Supportive Care Needs in long-term survivors of prostate cancer: 15-year follow-up of the NSW Prostate Cancer Care and Outcomes Study - Carolyn G Mazariego
• Pre-treatment Blautia abundance regulates chemotherapy-induced gastrointestinal toxicity risk: a pilot study - Kate Secombe
• Return to work in survivors of human papillomavirus-associated oropharyngeal cancer: an Australian experience - Claudia Zecena Morales

• Plenary: Controversies in mesothelioma - Why we should biopsy all patients with mesothelioma - Sonja Klebe
• Sparing patients a biopsy - cytological diagnosis of mesothelioma should be enough  - Amanda Segal
• Surgery in pleural mesothelioma – a 20 year controversy - John Edwards
• The patient perspective - Lynette David
• Is immunotherapy a panacea for mesothelioma? - Dean Fennell

Panel discussion at the end

• Intra-abdominal desmoid tumour – an unsual case of the acute abdomen - Fiona Bellamy
• Evaluation of a simplified Tumour-Node-Metastasis staging system in a population-based cancer registry - Chau Bui
• Oral capecitabine versus intravenous 5-Fluorouracil and Leucovorin in Stage II and III Colorectal Cancer : The Bendigo Experience 2007 - 2017 - Wanyuan Cui
• Colon Cancer Stage and Treatment Patterns in relation to culturally and linguistically diverse (CALD) Status, in South West Sydney Local Health District (SWSLHD). - Kirsten J Duggan
• Rectal Cancer Stage and Treatment Patterns in relation to patient’s culturally and linguistically diverse (CALD) Status, in South West Sydney Local Health District (SWSLHD).   - Kirsten J Duggan
• The safety and efficacy of colorectal cancer surgery in Queensland - Neal Rawson
• Can health service utilisation by gastrointestinal cancer patients be assessed using data from a biobank? - David Goldstein
• The association between body composition and stage of pancreatic cancer at diagnosis - Lauren Hanna
• Statistics on gastrointestinal cancers diagnosed in Australia - Justin Harvey
• Role of screening in geriatric population at risk of developing cancer treatment related toxicities - Kristin Hsu
• Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) – the other microsatellite instability - Andrew Laycock
• Presenting symptoms among oesophagogastric cancer patients at a regional Loddon Mallee hospital - Mwila Kabwe
• Mapping the optimal Care Pathway (OCP) for people with oesophagogastric cancer at two regional Victorian hospitals - Mwila Kabwe
• Mortality in early stage colorectal cancer: A comparative analysis between a regional and metropolitan centre in Victoria - Lisi Elizabeth Lim
• Changes in colorectal cancer (CRC) presentation over a 10 year period (2005-2016) in South Western Sydney Local Health District (SWSLHD) : results from a clinicopathological database - Sarah Maloney
• Impact of rural and remoteness on overall survival in Australian patients with Stage I-III colorectal cancer - Christina M Mullany
• WA Histology Data Collection Project: findings from Rounds 1-6 - Kathleen O'Connor
• Using a rapid improvement event to identify solutions to improve timelines of the oesophago-gastric cancer journey through a regional Victorian hospital - Carol Parker
• Retrospective analysis of clinical characteristics and outcomes for anal cancer patients in the South West Sydney Local Health District (SWSLHD) between 2010-2017 - Andrew O Parsonson
• Cancer Stem Cell Markers in Metastatic Gastroesophageal Adenocarcinoma - Sarennya Pathmanandavel
• Benchmarking the Optimum Surgical Utilization Rate for Common Gastrointestinal Tumours in Australia - Sathira Perera
• Western Australian Survival Data for Gastrointestinal Cancers 1995 to 2014 with comparative data for 5 other high-income countries. On behalf of the International Cancer Benchmarking Partnership (ICBP) - David Ransom
• Evaluation of nutrition outcomes and clinician compliance of an evidence based nutrition care pathway for upper GI cancer patients undergoing radical chemo-radiation therapy - Kirsty Rowan
• Capecitabine and temozolomide (CAPTEM) for intermediate to high grade metastatic neuroendocrine tumours (NET): A single centre experience. - Arvind Sahu
• Patterns of care and survival outcomes of younger versus older adults with stage I to IV rectal cancer at Concord Repatriation General Hospital - Mohsen Shafiei
• When is ‘enough’ data really too much? Data capture in the CIC Cancer Project - Mary Theophilus
• Gastro-Intestinal Cancers – Targeted therapy use is more prevalent in patients with left-side colon cancer in Australia - Inga Tinton
• Patterns of care for patients with oesophageal cancer in Victoria: data prior to implementation of Optimal Care Pathways - Victoria White
• Outcomes of patients with metastatic gastro-oesophageal cancer who received palliative systemic therapy in the Australian Capital Territory (ACT) - Desmond Yip
• A phase 1b trial of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma (uHCC) - Louise Young
• Participating in an International Stereotactic Radiotherapy Patient Registry - Eva Arneric
• Standardizing multidisciplinary approach for patients who are prescribed oral chemotherapy in our cancer centre - Tricia TB Bourke
• Victorian end-of-life care professionals’ attitudes toward voluntary assisted dying - Sarah Blaschke
• Implementing a highly accessible model of screening and assessment in geriatric oncology: our experience - Geoffrey Bryant
• Colorectal cancer patient reported outcomes: putting theory into practice. - Geoffrey Bryant
• Unmasking Anxiety: A qualitative investigation of health professionals’ perspectives of mask-anxiety in head and neck cancer. - Phyllis Butow
• Referral practices and patient outcomes in regional Victoria Oncology Care - Grace Chazan
• To evaluate the impact of a pharmacy driven protocol that converts standard rituximab infusions to subcutaneous for eligible patients. - Anna Choo
• Shared follow-up care for women with low-risk endometrial cancer   - Jennifer Chynoweth
• Position Statement on genetic testing for women diagnosed with ovarian cancer - Jennifer Chynoweth
• Beyond the data, what is the role of those affected by cancer in reimbursement decisions? - Greg Cook
• The Lung Cancer Framework: Optimising lung cancer service delivery - Jennifer Chynoweth
• Formative-process evaluation of the dietetic service and model of care provided to day therapy at Peter MacCallum Cancer Centre. - Jodi Dumbrell
• Improving outcomes for rural cancer survivors in Australia: new research questions from an international Churchill Fellowship - Kate Gunn
• The effect of new radiotherapy departments on the accessibility of cancer patients to the nearest radiotherapy facilities in NSW - Gabriel Gabriel
• Survey on patterns of travel for patients attending chemotherapy day units in Monash Health- a local experience - Chun Loo Gan
• Digging into context: a qualitative study of staff experiences during pre-implementation of the Australian Clinical Pathway for the Screening, Assessment and Management of Anxiety and Depression in Adult Cancer Patients. - Phyllis Butow
• Piperacillin/Tazobactam Use for Non-Neutropenic Fever in a Tertiary Hospital Medical Oncology Department - Sean Hill
• The effect of changes in indications for chemotherapy on the optimal chemotherapy utilisation rate in early breast cancer - Susannah Jacob
• Introduction of a Standardised On-treatment Radiation Mucositis Pain Management Protocol in a Head and Neck Cancer Oncology Unit - Elizabeth Kernutt
• Patient experience of a multidisciplinary optimisation clinic for cancer patients with complex needs - Nicole Kiss
• Enhanced supportive care program: Incorporating integrative oncology in a comprehensive cancer service - Judith Lacey
• An Innovative Nursing Model to Support Country People Receiving Oral Treatment for Cancer - Christine Henneker
• Description of the rationale and core domains of an antimicrobial stewardship in cancer specialist nursing role. - Belinda Lambros
• The Victorian Lung Cancer Service Redesign Program: Learnings Intended to Inform Development of Future Redesign Projects - Geraldine Largey
• The Victorian Lung Cancer Service Redesign Project: How Technology Enhanced Understanding of Project impact - Geraldine Largey
• Implementation of a validated chemotherapy prediction tool in a busy oncology clinic - Gabrielle Lie
• Implementation and results of the Victorian Cancer Patient Experience Survey (VCPES) at Monash Health - Caroline Lum
• The impact of parental cancer on preadolescent children (0–11 years) in Western Australia: A longitudinal population study - Jeneva L Ohan
• Safety from bag to vein: infusion management in a tertiary oncology centre - Jeanie Misko
• From Smartphone to Electronic Health Record (EHR): An Innovative Implementation of Patient-Reported Outcomes and Patient-Generated Health Data in Routine Cancer Care - Raghav Murali-Ganesh
• The growing problem of cancer in Victorian prisoners: A description of cancer diagnoses, demographics, risk factors and barriers to optimal care - Genni M Newnham
• Cancer costs experienced by Western Australian cancer patients - Jade C Newton
• Patterns of health service utilisation among the Australian population with cancer compared to the general population - Huah Shin Ng
• Potential length of stay reduction with outpatient management of low risk febrile neutropenia. - Tate Jacobson
• Improving chemotherapy quality and safety – VicTAG chemotherapy audit toolkit - Shaun O'Connor
• Building Clinical Trial Capability in Nascent Clinical Groups: Strategies and lessons learned - Evelien Rosens
• An audit of unplanned hospitalisations in oncology patients undergoing outpatient chemotherapy - Catherine Schembri
• Building and connecting a cancer workforce through collective impact. - Michelle Barrett
• How communication between cancer patients and their specialists affect the quality and cost of cancer care - Neli Slavova-Azmanova
• Delivering cancer clinical trials to as many people as possible, as close to home as possible: Icon’s Remote Access to Clinical Trials (ReACT) Program - Adam Stoneley
• Rural Cancer Awareness and Early Detection Initiative (RCAEDI) - Parth D Thaker
• Establishing Leadership in Regional Oncology within the Victorian Comprehensive Cancer Centre - Evelien Rosens
• Is there a role for GPs in patient care following a lung cancer diagnosis? An assessment of the communication between hospital physicians and primary care providers - Emily Watters
• Assessing oesophagogastric cancer care in Victoria against the optimal care pathway - Jane Weber
• Early detection of endometrial cancer following transvaginal ultrasound scan (TVS) performed in one centre of the United Kingdom collaborative trial of ovarian cancer screening (UKCTOCS): Long term survival data of screen detected cases. - Robert Woolas
• Piloting a web-based electronic Patient Reported Outcomes (ePRO) Portal for patients receiving CyberKnife radiotherapy treatment - Aylin Yahya
• Hearing patients’ children: A systematic review of the current interventions available for children living with parental cancer. - Georgia Halkett
• Cardiac monitoring practices in breast cancer patients receiving anthracyclines and HER-2 targeted agents – a single centre retrospective study - Graham Rivers
• Effect of exercise training on chemotherapy completion rates in individuals with cancer: A systematic review - Kelcey A Bland
• Successful etoposide phosphate desensitisation as management for an uncommon and poorly characterised hypersensitivity reaction – case report and review of literature - Michael Cain
• EX-MED Cancer: A Best Practice Exercise Medicine Program for People with Cancer - Prue Cormie
• Time to antibiotic administration in suspected febrile neutropenic patients presenting to Royal Darwin Hospital Emergency Department. - Stevie Cosentino
• Online learning improves nurse and pharmacist confidence in managing chemotherapy-induced nausea and vomiting (CINV) - Keith Cox
• Dose Modification for Haematological Toxicity: A survey of Australian Medical Oncologists - Wanyuan Cui
• The incidence and severity of breakthrough nausea and vomiting with palonosetron & dexamethasone requiring addition of NK1-receptor antagonists (NK1RA) in subsequent cycles in three highly or high-risk moderately emetogenic chemotherapy (HEC and high MEC) regimens - Eunice Dai
• Venous thromboembolism in patients with glioblastoma multiforme at the Royal Hobart Hospital. - Julia R Dixon-Douglas
• Rural Cancer Stories: the power of online, video-based, peer-directed information and support - Kate Gunn
• A psychosocial support program from Mamak Municipality  in Turkey for breast cancer patients; psychodrama group therapy and collaboration with the patients for screening and early diagnosis in the community.  - Derya Iren Akbiyik
• A systematic review of inventions to improve carer involvement in medical consultations and decision-making - Rachael Keast
• A web review of online advice for carers on how to engage in medical consultations and decisions - Rachael Keast
• Accelerating access to psychosocial services: Rapid Psychosocial Assessment Clinic     - Laura Kirsten
• An expanded role oncology pharmacist adds value to symptom and urgent review clinics - Chi Hao La
• Non-pharmacological Approach to Cancer related pain - Judith Lacey
• Psychosocial experiences of cancer survivors: A qualitative meta-review - Rebekah Laidsaar-Powell
• Expansion of TelePalliative Care in the home in regional Western Australia - Wei-Sen Lam
• Difficulties In Providing Palliative Care In Rural India (West Bengal) – Experience Of An NGO - Aditya Manna
• Feasibility and acceptability of an interactive web-portal for oncology patient physical activity and symptom tracking - Michael Marthick
• Development of Counterpart Navigator information app for women with a gynaecological cancer - Linda L Rehill
• Podcasts - a sound way for patients and carers to engage with cancer information - Annie Miller
• A retrospective review of toxicity and tolerability of weekly paclitaxel in early stage breast cancer (ESBC): a single centre experience - Christine Muttiah
• Nursing context of exercise promotion forpersons with haematological cancer - Matthew Perich
• The use of propofol in an acute hospice setting for continuous palliative sedation - Robert Wojnar
• Qualitative results of a phase II pilot randomised controlled trial of a lymphoma nurse-led survivorship model of care. - Karen M Taylor
• Retrospective study to understand the timeline and outcome of Aged Care Assessment of inpatients in the Palliative Care Unit at Redcliffe Hospital - Darshit Thaker
• Are existing delirium assessment tools appropriate for terminal delirium assessment among cancer patients? - Megumi Uchida
• Investigating Practices Relating to Supportive Care Screening in Victorian Cancer Services - Jane Weber
• Decision-making regarding cessation of endocrine therapies at the end of life - Betty Zhang
• Effects of supervised aerobic exercise on quality of life and fatigue in colorectal cancer patients undergoing adjuvant chemotherapy - Eva M Zopf

• Can genetic risk profiling aid risk categorization for colorectal cancer? - Mark Jenkins
• A gastroenterologist’s perspective of the implications of risk stratified colorectal cancer screening (including that based on genomic assessment) - Hooi C Ee
• Implementation of colorectal cancer risk prediction in primary care. - Jon Emery
• Policy implications of risk stratified colorectal cancer screening - Kathleen O'Connor

Panel discussion at the end

• Management of Malignant Pleural effusions - Rajesh Thomas
• Palliative care in mesothelioma - Fraser Brims
• Thoracic Malignancies: difficult pain management - Paul Glare
• Surgery for palliative symptom control in thoracic malignancy - John Edwards
• Palliative Radiation therapy in Malignant Pleural Mesothelioma - Mo Mo Tin

Chair: Chris Karapetis

• Hepatologist’s Perspective on the Management of HCC - Michael Wallace
• Surgical Management of Hepatocellular Cancer in Patients with Liver Disease - Bryon Jaques
• Stereotactic body radiotherapy for liver tumours – who should we treat? - Mark Lee
• The role of systemic therapy in primary HCC - Lara Lipton
• State of the Art and Emerging Interventional Radiology HCC management. - Shaun Samuelson

• Can Mammographic Breast Density Predict complete pathological response in Patients With Locally Advanced Breast Cancer following Neoadjuvant Chemotherapy? - Veenoo Agarwal
• Plasma Microparticle Proteome Reveals Potential Prognostic Biomarkers for the Colorectal Cancer - Seong Beom Ahn
• The ICCon Familial Cancer Database - C Nichols
• Precision breast and prostate cancer risk management: evidence-based translation of epigenetic testing - Melissa Southey

• The RAGE project: a step-wedge implementation of Rapid Access Gastrointestinal Endoscopy (RAGE) services in Melbourne. - Jon Emery
• “I had to tell my doctor that I had lung cancer”: communication between hospital- and community-based lung cancer care - Tara Nababan
• Radiotherapy utilisation in New South Wales (NSW) for selected cancers: Comparison of actual versus optimal rates and the influencing factors - Jesmin Shafiq
• Building Bridges: Addressing the Barriers and Facilitators to Support Sustainable Implementation of Community-based Shared Care for Depression in Cancer - Joanne Shaw
• Exploring nutrition knowledge, practice and education needs in regards to cancer malnutrition in the primary care and community sector - Jane Stewart
• The International Cancer Benchmarking Partnership: Routes to diagnosis for colorectal cancer - David P Weller

Genomics is facilitating a deeper understanding of cancer biology and through clinical research, new biomarkers are emerging that pave the way for next-generation therapeutics to help fight cancer in a more personalized way. Sandip Patel, MD, is a board-certified medical oncologist who specializes in cancer immunotherapy and early phase clinical trials involving immunotherapy across all types of cancer. Dr. Patel is focused on developing personalized therapies that stimulate a patient’s immune system to attack their specific tumor. He believes in offering these promising immunotherapeutics across all tumor types.

Chair: Libby Thomas, MD Illumina Australia Pty Ltd Sales Specialist

Speakers: Sandip P. Patel, MD Medical Oncologist Assistant Professor of Medicine US San Diego Health